Robert Marcus
Stock Analyst at JP Morgan
(1.53)
# 3,437
Out of 5,174 analysts
24
Total ratings
55.56%
Success rate
-0.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $175 | $155.92 | +12.24% | 11 | Feb 10, 2026 | |
| PEN Penumbra | Upgrades: Overweight | $275 → $370 | $334.17 | +10.72% | 5 | Dec 18, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $9.54 | +686.16% | 2 | Dec 17, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $105.23 | -52.49% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $108.92 | -86.23% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $29.61 | +92.50% | 2 | Jul 29, 2020 |
Becton, Dickinson and Company
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $175
Current: $155.92
Upside: +12.24%
Penumbra
Dec 18, 2025
Upgrades: Overweight
Price Target: $275 → $370
Current: $334.17
Upside: +10.72%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $9.54
Upside: +686.16%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $105.23
Upside: -52.49%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $108.92
Upside: -86.23%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $29.61
Upside: +92.50%